Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Moxidectin · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Moxidectin | DRUG | - |
| Midazolam | DRUG | - |
Inclusion criteria: 1. Men or women of nonchildbearing potential (WONCBP) aged 18 to 50 years inclusive at screening. WONCBP may be included if they are either surgically sterile (hysterectomy and/or oophorectomy) or postmenopausal for ≥1 year (with follicle-stimulating hormone \[FSH\] ≥38 mIU/...
Moxidectin is an investigational small molecule being studied in healthy volunteers and for infection. It is in Phase 1 clinical development. The drug has been evaluated in trials for its pharmacokinetics, excretion into breast milk, and potential drug interactions, though it is not approved for any indication.
Moxidectin is being developed by Pfizer, Inc., which trades under the ticker symbol PFE. The company is conducting early-stage clinical research on this small molecule drug candidate.
Moxidectin is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. All completed trials for Moxidectin are Phase 1 studies, and no active trials are currently listed.
Moxidectin has completed three Phase 1 trials. NCT00736697 studied the effect of a high-fat meal on bioavailability in 54 participants in France. NCT00751764 examined excretion into breast milk in 12 lactating women in the UK. NCT00856362 evaluated co-administration with midazolam in 38 healthy subjects in Germany.
Moxidectin is a distinct small molecule drug candidate. No alternative names have been reported for this compound. It is being studied independently by Pfizer for potential use in infections and healthy volunteer studies.